What we do
Boron neutron capture therapy (BNCT) drug development
Stella Pharma is the only company in the world with the technology needed to develop key boron compounds used in boron neutron capture therapy, an advanced technique for treating cancer. We also have boron concentration technology and facilities available nowhere in the world outside of Japan.
Thanks to the involvement of Sumitomo Heavy Industries, one of our shareholders, in the development of accelerator-based BNCT systems, we are a world leader in clinical trials involving accelerator-based BNCT systems and boron compounds.
Our proprietary technologies are drawing a high level of attention for their efficiency, and our SPM-011 boron compound development project was designated as a priority initiative by the Japanese government.